Muscle atrophy in diabetic patients with Charcot foot: a case-control study

Martin Berli, Nicolas Azaiez, Tobias Götschi, Christian W. A. Pfirrmann, İlker Uçkay, Reto Sutter, Felix W. A. Waibel, Andrea B. RosskopfSkeletal 2023 · DOI

TL;DR

Diabetic patients with Charcot foot (CF) exhibit significantly more severe muscle atrophy and edema in their feet compared to diabetic patients without CF. Interestingly, this muscle atrophy doesn't correlate with the severity of the active CF disease itself, but a reduced cross-sectional area of the flexor digitorum brevis muscle in the hindfoot (< 139 mm²) could serve as an indicator for CF.

What Problem Does This Paper Address?

Diabetes mellitus is notorious for its complications, including vascular issues, nerve damage (neuropathy), and problems with the musculoskeletal system. One particularly debilitating complication is Charcot foot (CF), an inflammatory condition affecting bones, joints, and soft tissues, leading to severe foot deformities and reduced quality of life. While muscle atrophy is a known feature in diabetic patients, its specific distribution and severity in the context of active Charcot foot, and its relationship to CF disease severity, remained largely uninvestigated. This study aims to fill that gap by comparing muscle changes in diabetic patients with and without CF and exploring potential correlations.

Methods

This was a retrospective case-control study. Researchers compared MRI scans of 35 diabetic patients with newly diagnosed active Charcot foot to 35 age- and gender-matched diabetic patients without CF. Two readers independently evaluated the MRI images for:

  • Fatty muscle infiltration: Assessed using the Goutallier classification (stages 1-4), later grouped into "mild" (stages 1-2) and "severe" (stages 3-4).
  • Muscle atrophy: Measured by cross-sectional area (CSA) of specific muscles in the midfoot and hindfoot.
  • Intramuscular edema: Graded on a four-point scale (0-3), later grouped into "none/mild" and "moderate/severe."
  • Charcot foot disease severity: Evaluated using the Balgrist Score, which considers soft tissue edema, bone marrow edema, joint destruction, and fractures.

Statistical analyses included interreader agreement assessment (Kappa coefficients), Mann-Whitney U tests for continuous variables, Fisher's exact tests for ordinal variables, and Spearman's rank correlation for assessing relationships. Receiver operating characteristic (ROC) curves were used to identify a potential diagnostic cutoff for muscle CSA.

Datasets

The study utilized retrospective MRI data from patients at Balgrist University Hospital. The dataset comprised 35 diabetic patients with newly diagnosed active Charcot foot and 35 age- and gender-matched diabetic patients without Charcot foot. No new datasets were introduced, and no benchmarks were established beyond the standard clinical scoring systems used.

Key Insights and Ideas

  • Muscle atrophy is a significant feature of active Charcot foot: The study strongly suggests that muscle atrophy, characterized by fatty infiltration and reduced muscle size, is not just present but more severe in diabetic patients with active CF.
  • Edema is also more pronounced in CF: Similar to atrophy, intramuscular edema was found to be significantly more frequent and severe in the Charcot foot group.
  • Atrophy doesn't track disease severity: A surprising finding is the lack of correlation between the degree of muscle atrophy (both fatty infiltration and CSA) and the clinical severity of the Charcot foot disease as measured by the Balgrist Score. This implies that muscle changes might be a consequence of diabetes itself or neuropathy, rather than a direct reflection of the current inflammatory state of the Charcot foot.
  • A specific muscle marker for CF: The flexor digitorum brevis muscle's cross-sectional area emerged as a potential diagnostic indicator. A CSA below 139 mm² in this muscle showed good sensitivity and specificity for differentiating Charcot foot from control cases.

Key Results

  • Fatty infiltration: Very frequent in both groups (94.1% overall), but significantly higher in the Charcot group (p=0.023). Severe fatty infiltration was also significantly more common in the Charcot group (p=0.004 for all muscles).
  • Intramuscular edema: Moderate/severe edema was significantly more frequent in the Charcot group (p-values < 0.001-0.003).
  • Cross-sectional area (CSA): CSA of hindfoot muscles was significantly smaller in the Charcot group across all assessed muscles (p < 0.001).
  • Diagnostic cutoff: A CSA of < 139 mm² for the flexor digitorum brevis muscle in the hindfoot achieved a sensitivity of 62.9% and a specificity of 82.9% for indicating Charcot foot disease.
  • Correlation: No significant correlation was found between the Balgrist Score and fatty muscle infiltration (p-values 0.06-0.49) or CSA values (p-values 0.06-0.25).

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective design: This limits the analysis to qualitative assessment of fatty infiltration and prevents quantitative measurements like Dixon-based analysis.
  • Single time point: MRIs were taken at one point in time, precluding longitudinal analysis of disease progression.
  • Limited patient data: Information on diabetes severity, neuropathy presence/severity, and blood glucose levels was not available for comparison.
  • Potential reader bias: While readers were blinded to clinical data, the presence of significant foot deformities in CF patients on MR images could have introduced a bias.
  • Exclusion of non-diabetic CF: The study focused solely on diabetic CF, meaning the results cannot be generalized to all cases of Charcot arthropathy.

Future work could involve:

  • Prospective studies: To confirm findings with larger patient cohorts and potentially include longitudinal assessments.
  • Quantitative fatty infiltration analysis: Using techniques like Dixon-based MRI.
  • Inclusion of non-diabetic CF patients: To broaden the applicability of findings.
  • Assessment of muscle atrophy in other body parts: To investigate potential systemic effects of Charcot disease.
  • Longitudinal studies: To elucidate the timeline of disease onset and progression and confirm results for patients with non-diabetic Charcot feet.

Summary updated

Abstract

Muscle atrophy and muscle edema are significantly more severe in diabetic patients with CF disease. Muscle atrophy does not correlate with the severity of active CF disease. A CSA < 139 mm<sup>2</sup> of the flexor digitorum brevis muscle in the hindfoot may indicate CF disease.
BibTeX
@inproceedings{berli2023muscle,
  author = {Martin Berli and Nicolas Azaiez and Tobias Götschi and Christian W. A. Pfirrmann and İlker Uçkay and Reto Sutter and Felix W. A. Waibel and Andrea B. Rosskopf},
  title = {{Muscle atrophy in diabetic patients with Charcot foot: a case-control study}},
  booktitle = {Skeletal},
  year = {2023},
  doi = {10.1007/s00256-023-04328-1},
}
Figure